• +55 (48) 3332-8400/8403
  • contato@cienp.org.br
  •  

Mês: setembro 2017

Diabetes drug shows promise in Parkinson disease

Asher Mullard There are no approved disease-modifying drugs for Parkinson disease, a neurodegenerative condition that affects 2–3% of people aged ≥65 years. Accumulating evidence suggests that GLP1 receptor agonists — incretin mimetics that researchers first developed for the treatment of diabetes — may have neuroprotective properties. A first randomized, placebo-controlled trial of AstraZeneca’s GLP1 receptor agonist exenatide now provides further support for these agents as possible Parkinson drugs, researchers report in The Lancet. The team of academic researchers ran aphase II trial of exenatide in 62 Parkinson patients, looking…

FDA approves first-in-class cancer metabolism drug

Asher Mullard The FDA approved Agios’ and Celgene’s enasidenib for acute myeloid leukaemia (AML), validating metabolism-modulating drugs as a means of killing cancer cells. Enasidenib (formerly AG-221) is a first-in-class inhibitor of mutated isocitrate dehydrogenase 2 (IDH2). The IDH enzymes normally metabolize isocitrate into α-ketoglutarate. When they are mutated in cancers, they also convert α-ketoglutarate into 2-hydroxyglutarate, an oncometabolite that causes cell differentiation defects by impairing histone demethylation. In clinical trials of enasidenib, 23% of treated patients had complete responses or complete responses with partial haematologic recovery…

FDA approves first-in-class cancer metabolism drug

The FDA approved Agios’ and Celgene’s enasidenib for acute myeloid leukaemia (AML), validating metabolism-modulating drugs as a means of killing cancer cells. Para acessar a publicação na íntegra clique  aqui Fonte: Nature Reviews Drug Discovery VOLUME 16 | SEPTEMBER 2017 | 593  …